ONCOTELIC PROVIDES YE 2022 FINANCIAL RESULTS COMPARED TO YE 2021 PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
17 avr. 2023 07h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) is providing a summary of its financial results for the year...
Oncotelic Announces Release of Pet2DAO Tokens (PDAO)
03 avr. 2023 07h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
Oncotelic Announces Pet2DAO Website is Live
20 mars 2023 08h00 HE
|
Oncotelic Therapeutics, Inc.
PDAO is to Revolutionize Decentralized Autonomous Organization AGOURA HILLS, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or...
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
13 mars 2023 08h00 HE
|
Oncotelic Therapeutics, Inc.
-The TGFβ1 and TGFβ3 isoforms are predictive --Validation of TGFβ2 as therapeutic target AGOURA HILLS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC)...
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer
06 févr. 2023 08h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer
25 janv. 2023 08h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage biotechnology company, with a planned IPO of...
Oncotelic Announces the launch of PDAO token
17 janv. 2023 08h00 HE
|
Oncotelic Therapeutics, Inc.
- PDAO is to Revolutionize Decentralized Autonomous Organization (DAO) AGOURA HILLS, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the...
Oncotelic Issues Year End Message to Shareholders
28 déc. 2022 08h00 HE
|
Oncotelic Therapeutics, Inc.
– JV continues to advance to its IPO- OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for 2023- OT-101 commercialization effort expanding on multiple fronts - Manufacturing...
Oncotelic Presents Clinical Data of Confirming TGF-β2 as the appropriate target for gliomas at JCA-AACR Meeting 2022
19 déc. 2022 08h00 HE
|
Oncotelic Therapeutics, Inc.
-Reduced TGF-β2, but not TGF-β1 nor TGF-β3, is associated with improved OS. AGOURA HILLS, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the...
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
30 nov. 2022 08h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...